- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00085501
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II Selection Design Trial Of Concurrent Chemotherapy + Cetuximab Vs. Chemotherapy Followed By Cetuximab In Advanced Non-Small Cell Lung Cancer (NSCLC)
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with a monoclonal antibody may kill more tumor cells. It is not yet known whether cetuximab is more effective when given at the same time as chemotherapy or following chemotherapy.
PURPOSE: This randomized phase II trial is studying how well giving cetuximab at the same time as combination chemotherapy works compared to giving cetuximab after combination chemotherapy in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
OBJECTIVES:
Primary
- Compare overall survival of patients with selected stage IIIB or stage IV non-small cell lung cancer treated with concurrent vs sequential paclitaxel, carboplatin, and cetuximab.
Secondary
- Compare response rates (confirmed and unconfirmed, complete and partial) in patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Correlate epidermal growth factor receptor polymorphisms and downstream biomarkers with response to cetuximab in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I (concurrent cetuximab): Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1, 8, and 15 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 8. Treatment repeats every 21 days for a total of 4 courses (12 weeks) in the absence of disease progression or unacceptable toxicity. Beginning on week 13, patients receive single-agent cetuximab IV over 1 hour once weekly in the absence of disease progression or unacceptable toxicity.
- Arm II (sequential cetuximab): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses (12 weeks) in the absence of disease progression or unacceptable toxicity. Beginning on week 13, patients receive single-agent cetuximab IV over 1 hour (over 2 hours on week 13 only) once weekly in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 180 patients (90 per treatment arm) will be accrued for this study within 9 months.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Alaska
-
Anchorage, Alaska, Spojené státy, 99508
- Alaska Regional Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Spojené státy, 94705
- Alta Bates Comprehensive Cancer Center
-
Burlingame, California, Spojené státy, 94010
- Peninsula Medical Center
-
Duarte, California, Spojené státy, 91010
- City of Hope Comprehensive Cancer Center
-
Greenbrae, California, Spojené státy, 94904
- Sutter Health Western Division Cancer Research Group
-
Greenbrae, California, Spojené státy, 94904
- Marin Cancer Institute at Marin General Hospital
-
Hayward, California, Spojené státy, 94545
- Saint Rose Hospital
-
Livermore, California, Spojené státy, 94550
- Valley Memorial Hospital
-
Los Angeles, California, Spojené státy, 90033-0804
- USC/Norris Comprehensive Cancer Center and Hospital
-
Oakland, California, Spojené státy, 94602
- Highland General Hospital
-
Oakland, California, Spojené státy, 94609
- CCOP - Bay Area Tumor Institute
-
Oakland, California, Spojené státy, 94609
- Summit Medical Center
-
Palm Springs, California, Spojené státy, 92262
- Comprehensive Cancer Center at Desert Regional Medical Center
-
Roseville, California, Spojené státy, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Spojené státy, 95816
- Sutter Cancer center
-
Sacramento, California, Spojené státy, 95819
- Mercy General Hospital
-
Sacramento, California, Spojené státy, 95817
- University of California Davis Cancer Center
-
San Francisco, California, Spojené státy, 94118
- California Pacific Medical Center - California Campus
-
San Pablo, California, Spojené státy, 94806
- J.C. Robinson, M.D. Regional Cancer Center
-
Sana Rosa, California, Spojené státy, 95405
- CCOP - Santa Rosa Memorial Hospital
-
-
Colorado
-
Denver, Colorado, Spojené státy, 80220
- Veterans Affairs Medical Center - Denver
-
Denver, Colorado, Spojené státy, 80204
- St. Anthony Central Hospital
-
Denver, Colorado, Spojené státy, 80217-3364
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
-
Fort Collins, Colorado, Spojené státy, 80524
- Poudre Valley Hospital
-
Montrose, Colorado, Spojené státy, 81401
- Montrose Memorial Hospital Cancer Center
-
Westminster, Colorado, Spojené státy, 80030
- St. Anthony North Hospital
-
Wheat Ridge, Colorado, Spojené státy, 80033
- Exempla Lutheran Medical Center
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30309
- Piedmont Hospital
-
Atlanta, Georgia, Spojené státy, 30342
- Saint Joseph's Hospital of Atlanta
-
Atlanta, Georgia, Spojené státy, 30342
- CCOP - Atlanta Regional
-
Atlanta, Georgia, Spojené státy, 30342
- Northside Hospital Cancer Center
-
Augusta, Georgia, Spojené státy, 30901
- Augusta Oncology Associates
-
Austell, Georgia, Spojené státy, 30106
- WellStar Cobb Hospital
-
Decatur, Georgia, Spojené státy, 30033
- Charles B. Eberhart Cancer Center at DeKalb Medical Center
-
Gainesville, Georgia, Spojené státy, 30501
- Northeast Georgia Medical Center
-
Lawrenceville, Georgia, Spojené státy, 30045
- Gwinnett Medical Center
-
Marietta, Georgia, Spojené státy, 30060
- Kennestone Cancer Center at Wellstar Kennestone Hospital
-
Riverdale, Georgia, Spojené státy, 30274
- Southern Regional Medical Center
-
Savannah, Georgia, Spojené státy, 31403
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
-
Valdosta, Georgia, Spojené státy, 31603
- Pearlman Comprehensive Cancer Center at South Georgia Medical Center
-
-
Hawaii
-
Aiea, Hawaii, Spojené státy, 96701
- Kapiolani Medical Center at Pali Momi
-
Honolula, Hawaii, Spojené státy, 96813
- Cancer Research Center of Hawaii
-
Honolulu, Hawaii, Spojené státy, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Spojené státy, 96813
- OnCare Hawaii, Incorporated - Lusitana
-
Honolulu, Hawaii, Spojené státy, 96813
- Queen's Cancer Institute at Queen's Medical Center
-
Honolulu, Hawaii, Spojené státy, 96813
- Straub Clinic and Hospital, Incorporated
-
Honolulu, Hawaii, Spojené státy, 96817
- OnCare Hawaii, Incorporated - Kuakini
-
Honolulu, Hawaii, Spojené státy, 96817
- St. Francis Medical Center
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83712
- St. Luke's Mountain States Tumor Institute - Boise
-
-
Illinois
-
Alton, Illinois, Spojené státy, 62002
- Saint Anthony's Hospital at Saint Anthony's Health Center
-
Maywood, Illinois, Spojené státy, 60153
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
Naperville, Illinois, Spojené státy, 60540
- Hematology Oncology Consultants Ltd.
-
Naperville, Illinois, Spojené státy, 60566
- Edward Hospital Cancer Center
-
-
Indiana
-
Beech Grove, Indiana, Spojené státy, 46107
- St. Francis Hospital and Health Centers
-
-
Iowa
-
Davenport, Iowa, Spojené státy, 52804
- Genesis Medical Center - West Campus
-
Davenport, Iowa, Spojené státy, 52803
- Genesis Regional Cancer Center at Genesis Medical Center
-
-
Kansas
-
Kansas City, Kansas, Spojené státy, 66160
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
Salina, Kansas, Spojené státy, 67401
- Salina Regional Health Center
-
Wichita, Kansas, Spojené státy, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70112
- Tulane Cancer Center
-
Shreveport, Louisiana, Spojené státy, 71101
- Cancer Treatment Center at Christus Schumpert St. Mary Place
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02118
- Cancer Research Center at Boston Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- University of Michigan Comprehensive Cancer Center
-
Ann Arbor, Michigan, Spojené státy, 48106-0995
- St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital
-
Ann Arbor, Michigan, Spojené státy, 48100
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, Spojené státy, 49017
- Cancer Care Center at Battle Creek Health System
-
Bay City, Michigan, Spojené státy, 48708
- Bay Regional Medical Center
-
Big Rapids, Michigan, Spojené státy, 49307
- Mecosta County General Hospital
-
Detroit, Michigan, Spojené státy, 48202
- Josephine Ford Cancer Center at Henry Ford Health System
-
Flint, Michigan, Spojené státy, 48532
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Spojené státy, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Spojené státy, 49503
- Lacks Cancer Center at Saint Mary's Mercy Medical Center
-
Grand Rapids, Michigan, Spojené státy, 49503
- Spectrum Health Cancer Care - Butterworth Campus
-
Grand Rapids, Michigan, Spojené státy, 49506
- Metropolitan Hospital
-
Grand Rapids, Michigan, Spojené státy, 49506
- Spectrum Health Hospital - Blodgett Campus
-
Holland, Michigan, Spojené státy, 49423
- Holland Community Hospital
-
Mount Clemens, Michigan, Spojené státy, 48043
- Mount Clemens General Hospital
-
Muskegon, Michigan, Spojené státy, 49443
- Hackley Hospital
-
Petoskey, Michigan, Spojené státy, 49770
- Northern Michigan Hospital
-
Pontiac, Michigan, Spojené státy, 48341-2985
- St. Joseph Mercy Hospital
-
Saginaw, Michigan, Spojené státy, 48601
- Seton Cancer Institute - Saginaw
-
Traverse City, Michigan, Spojené státy, 49684
- Munson Medical Center
-
Warren, Michigan, Spojené státy, 48903
- St. John Macomb Hospital
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39216
- University of Mississippi Medical Center
-
Kessler AFB, Mississippi, Spojené státy, 39534-2519
- Keesler Medical Center - Keesler Air Force Base
-
-
Missouri
-
Cape Girardeau, Missouri, Spojené státy, 63701
- St. Francis Medical Center
-
Gape Girardeau, Missouri, Spojené státy, 63701
- Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
-
Joplin, Missouri, Spojené státy, 64804
- Freeman Cancer Institute at Freeman Health System
-
Springfield, Missouri, Spojené státy, 65804
- St. John's Regional Health Center
-
Springfield, Missouri, Spojené státy, 65807
- Hulston Cancer Center at Cox Medical Center South
-
St. Louis, Missouri, Spojené státy, 63141
- CCOP - St. Louis-Cape Girardeau
-
St. Louis, Missouri, Spojené státy, 63141
- David C. Pratt Cancer Center at St. John's Mercy
-
-
Montana
-
Billings, Montana, Spojené státy, 59101
- CCOP - Montana Cancer Consortium
-
Great Falls, Montana, Spojené státy, 59405
- Great Falls Clinic
-
Great Falls, Montana, Spojené státy, 59405
- Big Sky Oncology
-
Great Falls, Montana, Spojené státy, 59405
- Sletten Regional Cancer Institute
-
-
New Jersey
-
Ridgewood, New Jersey, Spojené státy, 07450
- Valley Hospital - Ridgewood
-
-
New York
-
Glens Falls, New York, Spojené státy, 12801
- Adirondack Cancer Care
-
Rochester, New York, Spojené státy, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28203
- Blumenthal Cancer Center at Carolinas Medical Center
-
Goldsboro, North Carolina, Spojené státy, 27534
- Wayne Memorial Hospital, Incorporated
-
Hendersonville, North Carolina, Spojené státy, 28791
- Pardee Memorial Hospital
-
Rutherfordton, North Carolina, Spojené státy, 28139
- Rutherford Hospital
-
-
Ohio
-
Akron, Ohio, Spojené státy, 44307
- McDowell Cancer Center at Akron General Medical Center
-
Cincinnati, Ohio, Spojené státy, 45220
- Tri-Health Good Samaritan Hospital
-
Cleveland, Ohio, Spojené státy, 44195
- Cleveland Clinic Taussig Cancer Center
-
Dayton, Ohio, Spojené státy, 45428
- Veterans Affairs Medical Center - Dayton
-
Dayton, Ohio, Spojené státy, 45405
- Grandview Hospital
-
Dayton, Ohio, Spojené státy, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, Spojené státy, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, Spojené státy, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, Spojené státy, 45429
- CCOP - Dayton
-
Independence, Ohio, Spojené státy, 44131
- Community Oncology Group - Independence
-
Kettering, Ohio, Spojené státy, 45429
- Charles F. Kettering Memorial Hospital
-
Mansfield, Ohio, Spojené státy, 44903
- MedCentral - Mansfield Hospital
-
Middletown, Ohio, Spojené státy, 45044
- Middletown Regional Hospital
-
Troy, Ohio, Spojené státy, 45373
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wooster, Ohio, Spojené státy, 44691
- Cleveland Clinic - Wooster
-
Wright-Patterson Afb, Ohio, Spojené státy, 45433-5529
- United States Air Force Medical Center Wright-Patterson
-
Xenia, Ohio, Spojené státy, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
Oregon
-
Bend, Oregon, Spojené státy, 97701
- St. Charles Medical Center
-
Glesham, Oregon, Spojené státy, 97030
- Legacy Mount Hood Medical Center
-
Milwaukie, Oregon, Spojené státy, 97222
- Providence Milwaukie Hospital
-
Portland, Oregon, Spojené státy, 97225
- CCOP - Columbia River Oncology Program
-
Portland, Oregon, Spojené státy, 97225
- Providence St. Vincent Medical Center
-
Portland, Oregon, Spojené státy, 97210
- Comprehensive Cancer Center at Legacy Good Samaritan Hospital & Medical Center
-
Portland, Oregon, Spojené státy, 97213
- Providence Cancer Center at Providence Portland Medical Center
-
Portland, Oregon, Spojené státy, 97227
- Institute of Oncology at Vilnius University
-
Salem, Oregon, Spojené státy, 97309
- Salem Hospital Regional Cancer Center
-
Tualatin, Oregon, Spojené státy, 97062
- Legacy Meridian Park Hospital
-
-
South Carolina
-
Anderson, South Carolina, Spojené státy, 29621
- Rose Ramer Cancer Clinic at Anderson Area Medical Center
-
Charleston, South Carolina, Spojené státy, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
Florence, South Carolina, Spojené státy, 29506
- McLeod Regional Medical Center
-
Greenville, South Carolina, Spojené státy, 29615
- CCOP - Greenville
-
Greenville, South Carolina, Spojené státy, 29601
- Bon Secours St. Francis Health System
-
Greenville, South Carolina, Spojené státy, 29605
- Greenville Hospital System Cancer Center
-
Spartanburg, South Carolina, Spojené státy, 29303
- Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
-
Spartanburg, South Carolina, Spojené státy, 29304
- CCOP - Upstate Carolina
-
-
Tennessee
-
Knoxville, Tennessee, Spojené státy, 37916
- Thompson Cancer Survival Center
-
-
Texas
-
Arlington, Texas, Spojené státy, 76012
- Arlington Cancer Center - Arlington
-
Fort Sam Houston, Texas, Spojené státy, 78234
- Brooke Army Medical Center
-
Lackland AFB, Texas, Spojené státy, 78236
- Wilford Hall Medical Center
-
Lubbock, Texas, Spojené státy, 79415
- UMC Southwest Cancer and Research Center
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84112
- Huntsman Cancer Institute at University of Utah
-
-
Virginia
-
Danville, Virginia, Spojené státy, 24541
- Danville Regional Medical Center
-
Martinsville, Virginia, Spojené státy, 24115
- Memorial Hospital of Martinsville and Henry County
-
-
Washington
-
Bellingham, Washington, Spojené státy, 98225
- St. Joseph Hospital Community Cancer Center
-
Bremerton, Washington, Spojené státy, 98310
- Olympic Hematology and Oncology
-
Mt. Vernon, Washington, Spojené státy, 98273
- Cancer Care Center at Skagit Valley Hospital
-
Seattle, Washington, Spojené státy, 98104
- Harborview Medical Center
-
Seattle, Washington, Spojené státy, 98104
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Spojené státy, 98195
- University Cancer Center at University of Washington Medical Center
-
Seattle, Washington, Spojené státy, 98104
- Group Health Central Hospital
-
Seattle, Washington, Spojené státy, 98114
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
-
Spokane, Washington, Spojené státy, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, Spojené státy, 99204
- Providence Cancer Center at Sacred Heart Medical Center
-
Spokane, Washington, Spojené státy, 99207
- Providence Cancer Center at Holy Family Hospital
-
Vancouver, Washington, Spojené státy, 98668
- Southwest Washington Medical Center Cancer Center
-
Wenatchee, Washington, Spojené státy, 98801
- Central Washington Hospital
-
Wenatchee, Washington, Spojené státy, 98801
- Wenatchee Valley Clinic
-
Yakima, Washington, Spojené státy, 98902
- North Star Lodge Cancer Center
-
Yakima, Washington, Spojené státy, 98902
- Washington Hematology - Oncology Specialists
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of one of the following stages:
- Newly diagnosed selected stage IIIB disease (T4 lesion due to malignant pleural effusion, any N, M0)
- Newly diagnosed stage IV disease (any T, any N, M1)
- Recurrent stage IV disease after prior surgery or radiotherapy
The following subtypes are eligible:
- Adenocarcinoma
- Squamous cell carcinoma
- Large cell carcinoma
- Unspecified
Measurable disease by CT scan, MRI, x-ray, or physical exam
- Pleural effusions, ascites, or laboratory parameters are not acceptable as the only evidence of disease
- Not within prior radiotherapy field unless a new lesion is present
- Not within area of prior surgical resection
- No known brain metastases by CT scan or MRI
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9 mg/dL
Hepatic
- Bilirubin ≤ 2 times upper limit of normal (ULN)
- SGOT or SGPT ≤ 2 times ULN
- Alkaline phosphatase ≤ 2 times ULN
- No known acute hepatitis
Renal
- Creatinine ≤ ULN
- Creatinine clearance ≥ 50 mL/min
Cardiovascular
- No significant cardiac disease
- No uncontrolled hypertension
- No unstable angina
- No congestive heart failure
Other
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
- No active or uncontrolled infection
- No sensory neuropathy ≥ grade 2
- No known human anti-mouse antibodies
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior biologic therapy for NSCLC
- No prior chimeric or murine monoclonal antibody therapy
- No prior cetuximab
Chemotherapy
- No prior systemic chemotherapy for NSCLC
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- At least 3 weeks since prior radiotherapy and recovered
Surgery
- See Disease Characteristics
- At least 2 weeks since prior thoracic or major surgery and recovered
Other
- No prior gefitinib or other investigational agents that target the epidermal growth factor receptor pathway
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: 2
|
Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2. Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14. Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2 Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1 Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4. Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1. |
|
Aktivní komparátor: 1
|
Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2. Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14. Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2 Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1 Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4. Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Select a regimen based on overall survival
Časové okno: From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
To select a regimen based on overall survival via a Phase II selection design of chemotherapy in conjunction with cetuximab (concurrent vs. sequential) for Phase III testing against chemotherapy alone in Stage IIIB and Stage IV non-small cell lung cancer.
|
From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
|
Response rate (confirmed and unconfirmed, complete and partial response)
Časové okno: From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
To evaluate response rates (confirmed and unconfirmed, complete and partial) of patients with selected Stage IIIB and Stage IV NSCLC treated with paclitaxel and carboplatin with concurrent cetuximab or paclitaxel and carboplatin followed by cetuximab.
|
From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
|
Toxicities
Časové okno: From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
To evaluate the toxicities of the two treatment regimens in patients with selected Stage IIIB and Stage IV NSCLC.
|
From date of registration until the date of progression or date of death from any cause, whichever came first, assessed up to 3 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Correlation of epidermal growth factor receptor polymorphisms and downstream biomarkers with response
Časové okno: At prestudy
|
To conduct exploratory molecular correlative studies of the EGFR-HER signaling pathways examining activated phosphoproteins, oncogenic mutations and rates of proliferation and apoptosis in patient tissues (see S9925 for details).
|
At prestudy
|
|
Evaluate EGFR polymorphisms
Časové okno: At prestudy and week 5
|
To evaluate EGFR polymorphisms as a potential correlate for response to cetuximab (see S9925 for details).
|
At prestudy and week 5
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Karen Kelly, MD, University of Colorado, Denver
- Vrchní vyšetřovatel: Roy S. Herbst, MD, PhD, M.D. Anderson Cancer Center
- Vrchní vyšetřovatel: David R. Gandara, MD, University of California, Davis
Publikace a užitečné odkazy
Obecné publikace
- Franklin WA, Gandara DR, Kim ES, et al.: SWOG S0342 and S0536: expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 27 (Suppl 15): A-11076, 2009.
- Mack PC, Holland WS, Redman M, et al.: KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. [Abstract] J Clin Oncol 27 (Suppl15): A-8022, 2009.
- Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10;26(20):3351-7. doi: 10.1200/JCO.2007.14.0111.
- Herbst RS, Chansky K, Kelly K, et al.: A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. [Abstract] J Clin Oncol 25 (Suppl 18): A-7545, 395s, 2007.
- Kelly K, Herbst RS, Crowley JJ, et al.: Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): a randomized phase II selectional trial SWOG 0342. [Abstract] J Clin Oncol 24 (Suppl 18): A-7015, 367s, 2006.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci dýchacích cest
- Novotvary
- Plicní onemocnění
- Novotvary podle místa
- Novotvary dýchacího traktu
- Novotvary hrudníku
- Karcinom, Bronchogenní
- Bronchiální novotvary
- Novotvary plic
- Karcinom, nemalobuněčné plíce
- Molekulární mechanismy farmakologického působení
- Antineoplastická činidla
- Tubulinové modulátory
- Antimitotické látky
- Modulátory mitózy
- Antineoplastické látky, fytogenní
- Antineoplastická činidla, Imunologická
- Karboplatina
- Paklitaxel
- Cetuximab
Další identifikační čísla studie
- CDR0000370806
- U10CA032102 (Grant/smlouva NIH USA)
- S0342 (Jiný identifikátor: SWOG)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Rakovina plic
-
Xiangya Hospital of Central South UniversityZatím nenabírámeNon Small Cell Lung | Metastázy v mozkuČína
-
Argentinian Intensive Care SocietyDokončenoDechová frekvence | End-exspiratory Lung Impedance | Zlomek tloušťky membrány | Exkurze brániceArgentina
-
Indiana UniversityRichard L. Roudebush VA Medical CenterDokončeno
-
Novartis PharmaceuticalsDokončenoNeuroendokrinní nádory | Advanced NET of GI Origin | Advanced NET of Lung OriginSpojené státy, Kolumbie, Itálie, Tchaj-wan, Spojené království, Belgie, Česko, Německo, Japonsko, Saudská arábie, Kanada, Holandsko, Španělsko, Korejská republika, Libanon, Rakousko, Čína, Řecko, Jižní Afrika, Thajsko, Maďarsko, Krocan a více
-
University Hospital, Clermont-FerrandCentral Hospital, Nancy, FranceDokončenoDítě, Pouze | Spontánní pneumotorax | Idiopatický pneumotorax | Bleb LungFrancie
-
University of LorraineDokončenoDítě, Pouze | Spontánní pneumotorax | Idiopatický pneumotorax | Bleb LungFrancie
-
Assiut UniversityZatím nenabírámeRakovina plic | Poranění plic | Bleb Lung
-
Jiangsu HengRui Medicine Co., Ltd.DokončenoNon Small Cell LungČína
-
SanofiRegeneron PharmaceuticalsDokončenoKarcinom | Non Small Cell LungSpojené státy, Francie, Kanada, Německo, Holandsko, Portugalsko, Španělsko, Švédsko, Čína, Bulharsko, Estonsko, Indie, Malajsie, Singapur, Tchaj-wan, Argentina, Rakousko, Finsko, Maďarsko, Itálie, Austrálie, Chile, Hongkong, Polsko, Řecko, ... a více
-
Taichung Veterans General HospitalDokončenoKardiotoxicita | Nádor plic bez malých buněk (MeSH termín: Carcinoma, Non-Small-Cell Lung) | Lékové nežádoucí účinky a nežádoucí reakce (MeSH termín) | Inhibitor tyrozinkinázy EGFRTchaj-wan
Klinické studie na cetuximab
-
Zhejiang UniversityNáborKolorektální novotvary | Fruquintinib | BRAF | RAS | CetuximabβČína
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterNáborSpinocelulární karcinom hlavy a krku | Posouzení maržeHolandsko
-
Meng QiuZatím nenabírámeKapecitabin | Kolorektální karcinom (CRC) | CetuximabČína
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityNáborKolorektální rakovina | Kapecitabin | CetuximabČína
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCDokončenoMetastatický kolorektální karcinomRakousko
-
Eben RosenthalNational Cancer Institute (NCI)UkončenoAdenokarcinom pankreatuSpojené státy
-
HiberCell, Inc.UkončenoKolorektální karcinomSpojené státy, Portoriko, Německo, Francie
-
Merck KGaA, Darmstadt, GermanyDokončenoDříve neléčený metastatický kolorektální karcinomFrancie, Itálie, Polsko, Německo, Hongkong, Rakousko, Brazílie, Izrael, Řecko, Argentina, Thajsko, Belgie, Austrálie, Mexiko
-
Cancer Institute and Hospital, Chinese Academy...Nábor
-
Poitiers University HospitalDokončenoMetastatická rakovina tlustého střevaFrancie